Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119

Author(s): Parmissa Randhawa, Aeli P. Olson, Shaohuang Chen, Kaley Lexi Gower-Fry, Cornelia Hoehr, Jonathan W. Engle, Caterina F. Ramogida, Valery Radchenko*

Journal Name: Current Radiopharmaceuticals

Volume 14 , Issue 4 , 2021

Become EABM
Become Reviewer
Call for Editor


Targeted Radionuclide Therapies (TRTs) based on Auger emitting radionuclides have the potential to deliver extremely selective therapeutic payloads on the cellular level. However, to fully exploit this potential, suitable radionuclides need to be applied in combination with appropriate delivery systems. In this review, we summarize the state-of-the-art production, purification, chelation and applications of two promising candidates for Targeted Auger Therapy, namely antimony- 119 (119Sb) and mercury-197 (197Hg). Both radionuclides have great potential to become efficient tools for TRT. We also highlight our current progress on the production of both radionuclides at TRIUMF and the University of Wisconsin.

Keywords: Targeted Radionuclide Therapy (TRT), auger electrons, mercury-197 (197Hg), antimony-119 (119Sb), production, radiochemical separation, coordination, imaging, dosimetry.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 11 January, 2021
Page: [394 - 419]
Pages: 26
DOI: 10.2174/1874471014999210111201630
Price: $95

Article Metrics

PDF: 246